Global CAR-T Cell Therapy Market is expected to grow at a CAGR of 9.1% during the forecast period 2024-2031.
Chimeric antigen receptor T-cell therapy, often referred to as CAR-T therapy, is a treatment method where a patient’s T cells are genetically modified to produce chimeric antigen receptor (CAR) T-cells. These engineered cells are designed to recognize and more effectively eliminate cancer cells. CARs are proteins that enable T cells to identify an antigen present on specific tumor cells.
Even months after the infusion process, CAR-T cells may persist in the body and help prevent the recurrence of cancer cells. CAR-T cell therapy is an extremely promising emerging treatment for cancer patients and is increasingly favored over traditional methods such as chemotherapy, surgery, and radiation therapy.
For More Insights Request Free Sample: https://www.datamintelligence.com/download-sample/car-t-cell-therapy-market
-
CD 19
-
CD 20
-
GD2
-
CD22
-
CD30
-
CD33
-
HER1
-
HER2
-
Meso
-
EGFRV III
By Therapeutic Application
-
Acute Lymphoblastic Leukemia (ALL)
-
Chronic lymphocytic leukemia (CLL)
-
Non-Hodgkin lymphoma
-
Acute myeloid leukemia (AML)
-
Neuroblastoma
-
Multiple myeloma (MM)
Major players are Pfizer, Inc. Novartis AG, Juno Therapeutics, Inc. (Celgene Corporation), Kite Pharma, Inc. (Gilead Sciences Inc.), bluebird bio (Celgene Corporation), Bellicum Pharmaceuticals, Inc, Immune Therapeutics, Inc, Cellectis, Sorrento Therapeutics, Inc and CARsgen Therapeutics, Ltd.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian